# Ultrafast MR imaging findings of 2 different subtypes in a male patient with bilateral breast cancer

**Authors:** Kyle Kleiman, Ceren Yalniz, Stefanie Woodard

PMC · DOI: 10.1016/j.radcr.2023.12.043 · Radiology Case Reports · 2024-01-15

## TL;DR

This case report describes a rare instance of bilateral male breast cancer with different subtypes, highlighting how ultrafast MRI can help distinguish between them.

## Contribution

The paper demonstrates the use of ultrafast MRI to differentiate between breast cancer subtypes in a male patient.

## Key findings

- Ultrafast MRI showed significant enhancement differences between two distinct breast cancer subtypes.
- Metrics like time-to-enhancement and maximum slope may help identify and predict cancer subtypes.
- The findings suggest ultrafast MRI could serve as a prognostic tool for breast cancer subtypes.

## Abstract

Bilateral breast cancer in males is an exceedingly rare diagnosis. In this case report, we will discuss the ultrafast sequence findings of a bilateral male breast cancer with different subtypes on his staging dynamic contrast enhanced (DCE) MRI with ultrafast technique. A 94-year-old male presented with bilateral palpable complaints in his breasts. Diagnostic mammography and ultrasound images demonstrated bilateral irregular masses with nipple retraction. Biopsies were performed and the histopathologic examination revealed invasive breast carcinoma of no special type in 1 breast and invasive micropapillary carcinoma in the other breast. Staging MRI with ultrafast sequence showed significant enhancement differences between 2 different subtypes, correlating with the different levels of tumor aggressiveness. Different ultrafast metrics, such as time-to-enhancement and maximum slope, may help to differentiate between several subtypes of breast cancer and serve as prognostic indicators. This case report discusses the application of ultrafast sequence in predicting breast cancer subtypes in a male patient with bilateral disease.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989), invasive breast carcinoma (MONDO:0006256)

## Full-text entities

- **Genes:** CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}
- **Diseases:** benign lesions of the breast (MESH:D061325), Male breast cancer (MESH:D018567), Invasive breast carcinoma (MESH:D001943), squamous cell carcinoma (MESH:D002294), axillary lymph node metastasis (MESH:D008207), metastatic disease (MESH:D000092182), Malignant tumors (MESH:D009369), bladder cancer (MESH:D001749), invasive ductal carcinoma (MESH:D044584), malignant breast lesions (MESH:D001941), obesity (MESH:D009765), melanoma (MESH:D008545), Invasive micropapillary carcinoma (MESH:D009361), benign lesions (MESH:D001932)
- **Chemicals:** palbociclib (MESH:C500026), letrozole (MESH:D000077289)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10823031/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10823031/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC10823031/full.md

---
Source: https://tomesphere.com/paper/PMC10823031